Drugs / SNUH-CD19-CAR-T
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05210907 | Feb 2022 → Sep 2025 overdue | B-cell acute lymphoblastic leukemia | Seoul National University Hospital | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06247501 | Jan 2024 → Dec 2028 expected | B-cell acute lymphoblastic leukemia | Seoul National University Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SNUH-CD19-CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06247501 ↗ |
| Modality | Cell therapy | “Chimeric antigen receptor T cells (CAR-T cells)” NCT05210907 ↗ |
| Route | Intravenous | “SNUH-CD19-CAR-T is administered as an intravenous infusion.” NCT05210907 ↗ |
| Target | CD19 | “target CD19 on the surface of B-cells” NCT06247501 ↗ |